Skip to content
BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) · SMALL CAP

Aptose Biosciences Inc. APTOF

9 fiscal years on record · USD · FY2025 reported · SEC filings only
$0
$-25.5M
$-22.0M

Slide the table for earlier years · "·" marks a figure not available in our data for that year.

Growth

USD 0.00
Revenue, FY2025 · full 9-year series below
Revenue $M Net income $M
FY2025 · Revenue 0.0 · Net income -25.5
-25.0M-50.0M
2017202020232025
Compound annual growth
3 yrs
5 yrs
10 yrs
15 yrs

Compound annual rates per period — left blank where that exact year isn't on file, the series crosses a loss, or (per-share rows) a split falls inside the window.

Profitability

·
ROE
FY2022 · ROE -74.7%
-100%-200%
201720212025
Three returns, three denominators.
Return on equityNot applicable: equity was zero or negative in this period, so return on equity has no meaning.
Return on capital employedNot available: we don't have a clean operating profit figure for this period.

Cash & shareholders

·
returned in FY2025 · dividends + net buybacks
Free cash flow $M
FY2025 · FCF -22.0
-20M-40M
201720212025

Total assetsUSD 10.0M
EquityUSD -27.2M
CashUSD 935,000.00
Current ratio0.69×

Equity funds -271% of total assets.

The 9-year record

9 fiscal years
Every figure from documents filed with the SEC · USD

EPS, diluted, dividend per share and shares outstanding are shown without shading, and a vertical line marks the year the share count changed — the series crosses a large, unexplained change in share count, so the years on either side are not on a comparable scale.

row low → row highnegative—not applicable◌not available in our data
APTOF, 9-year financial record
Metric 202520242023202220212020201920182017
Revenue $B0.00.00.00.00.00.0◌◌◌
Operating income $B◌◌◌◌◌◌◌◌◌
EBITDA $B◌◌◌◌◌◌◌◌◌
Income tax $B0.00.0◌◌◌◌◌◌◌
Net income $B−0.0−0.0−0.1−0.0−0.1−0.1−0.0−0.0−0.0
Free cash flow $B−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0
EPS, diluted $−10.41−36.38−227.43−6.80−0.73−0.67−0.52−0.86−0.52
Dividend / sh $◌◌◌◌◌◌◌◌◌
Payout % — not applicable: no dividend—————————
ROE %———−74.7−67.7−51.9−48.7−237.8−114.1
Shares out B0.000.000.010.090.090.090.080.040.03

Slide the table for earlier years. "—" not applicable · "◌" not available in our data.

More in this sector

Other companies filing in the same sector

Provenance

Company facts, as filed

How we verify · 0 failures in 36 reconciliationsAUDITED

Reconciled in 9 of the 9 fiscal years we could check. 20 checks were skipped: the balance sheet is not tagged before 2017. 10 checks were skipped: EPS is not tagged before 2017.

EPS recomputationBalance-sheet identityGross profitBalance-sheet liquidityCurrency consistency0 failures
ActivityBiological Products, (No Diagnostic Substances)
Listed onnot stated in the filings
Incorporated inoutside the United States — SEC code A6
Fiscal year endsDecember 31
SEC categorysmaller reporting company
Data on record since2017

Share this section

Download image